Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iguratimod in Active Primary Sjogren's Syndrome
NCT04830644Phase 2Unknown
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Mar 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of iguratimod in primary Sjögren's syndrome, sponsored by Simcere Pharmaceutical Group. Status: unknown.
02
Drugs
iguratimod
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on NCT04830644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04830644.